AVTX
Avalo Therapeutics Inc
15.70$
+2.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.7% | 99.8% | 98.2% | 25.5% | 31.2% | 49.1% | 59.4% | 77.1% | 49.2% | 40.0% | 92.1% | 90.4% | |
| 95.3% | 97.7% | 88.9% | 5.7% | 15.2% | 10.0% | 43.2% | 68.0% | 39.5% | 35.3% | 89.3% | 13.6% | |
| 95.3% | 97.7% | 88.9% | 5.7% | 15.2% | 31.1% | 43.2% | 68.0% | 39.5% | 35.3% | 89.3% | 84.4% | |
| – | – | 2.3% | 6.8% | 8.7% | 14.5% | 10.0% | 6.0% | 5.8% | 0.6% | 0.4% | – | |
| – | – | 0.2% | 0.9% | 1.6% | 0.1% | 0.0% | 0.0% | 0.1% | 0.0% | – | – | |
| – | – | – | 0.1% | 0.8% | 4.0% | 3.7% | 3.4% | 7.2% | – | – | – | |
| – | – | – | 33.1% | 23.4% | 39.9% | 32.9% | 18.0% | 43.2% | 50.0% | 7.0% | 9.0% | |
| – | – | – | 41.0% | 44.5% | 6.7% | 3.6% | 0.0% | – | – | – | – | |
| 313.8% | 39.6% | 96.4% | 35.4% | 70.2% | 41.9% | 43.9% | 71.2% | 132.7% | 65.2% | 11.7% | 28.7% | |
| 40.5% | 27.0% | 74.7% | 26.5% | 37.3% | 33.7% | 34.8% | 24.8% | 66.3% | 22.0% | 4.6% | 11.1% | |
| 15.5% | 14.8% | 40.8% | – | 1.5% | 0.4% | 1.0% | 0.6% | 19.4% | 2.6% | 0.4% | 0.3% | |
| 7.6% | 3.1% | 17.5% | 3.0% | 2.1% | 5.8% | 5.9% | 4.2% | 8.6% | 2.1% | 0.2% | 0.1% | |
| – | – | – | – | 20.4% | – | – | 40.9% | 40.4% | – | – | – | |
| -213.8% | 60.4% | 3.6% | 64.6% | 29.8% | 58.1% | 56.1% | 28.8% | -32.7% | 34.8% | 88.3% | 71.3% | |
| -349.7% | -247.3% | -1,214.0% | -134.9% | -139.8% | -316.5% | -406.3% | -326.8% | -910.6% | -1,596.4% | -245.6% | -385.1% | |
| 3.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.1% | 1.3% | 7.2% | 11.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.